Demolli Pashija, Frey Diana
University Hospital Zurich (USZ), Department of Rheumatology, Switzerland.
Bone Rep. 2024 Sep 11;22:101803. doi: 10.1016/j.bonr.2024.101803. eCollection 2024 Sep.
Osteoporosis and decreased bone density is a frequent complication of anorexia nervosa (AN). As of yet, there have been no studies of accomplished treatment of AN-related osteoporosis with romosuzumab, a monoclonal antibody to sclerostin. We report the first case of a premenopausal, 29-year old patient in Switzerland with decreased bone density and osteoporotic fractures due to anorexia nervosa, who completed the treatment with romosuzumab. There was a significant increase in bone mineral density (BMD) after 12 months of therapy. No serious side effects were reported. To date, only bisphosphonates, denosumab and teriparatide have been evaluated in treatment of AN-related osteoporosis in adolescents and premenopausal individuals respectively. Our report demonstrates that romosuzumab might be an alternative treatment option in patients with anorexia nervosa who are at high risk for osteoporotic fractures. To assess the efficacy and safety of romosuzumab in individuals with AN further studies are needed.
骨质疏松症和骨密度降低是神经性厌食症（AN）常见的并发症。截至目前，尚未有关于使用抗硬化蛋白单克隆抗体罗莫单抗治疗AN相关骨质疏松症的研究。我们报告了瑞士首例因神经性厌食症导致骨密度降低和骨质疏松性骨折的29岁绝经前患者，该患者完成了罗莫单抗治疗。治疗12个月后骨矿物质密度（BMD）显著增加。未报告严重副作用。迄今为止，双膦酸盐、地诺单抗和特立帕肽分别已在青少年和绝经前个体中评估用于治疗AN相关骨质疏松症。我们的报告表明，罗莫单抗可能是骨质疏松性骨折高危神经性厌食症患者的一种替代治疗选择。需要进一步研究以评估罗莫单抗在AN患者中的疗效和安全性。
